Skip to main content

Search

Reset all filters
358 Result(s)
Sort by

Glyxambi®

Glyxambi®

Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
How BI Supports Grass Roots Innovation

How BI Supports Grass Roots Innovation

Hear from life-science entrepreneurs about how we are supporting early-stage science through our innovative Grass Roots program.
Rabisin® / Raboral V-RG®

Rabisin® / Raboral V-RG®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
Recombitek®

Recombitek®

Recombitek® offers a complete line of canine vaccines against distemper, major circulating strains CPV-2a, 2b, 2c, prevention of disease and shedding against leptospirosis.
Praxbind®

Praxbind®

Praxbind® is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoaculant effects is required: for emergency surgery/urgent procedures; in life-threa
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Rabisin® / Imrab®

Rabisin® / Imrab®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management